Far be it for me to question the Food & Drug Administration regarding their decision over a year ago to approve two new oral anticoagulants for use in preventing stroke in atrial fibrillation .  But as I noted last week, a study was just published in the Archives of Internal Medicine concluding that these new oral anticoagulants increased risk of bleeding in patients prescribed anti-platelet agents in response to an acute coronary syndrome .